Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Renovascular hypertension is caused by renovascular disease and it can be potentially cured by ablative or reconstructive operation or PTA. The incidence of renovascular hypertension is 1 to 2 per cent among nonselected hypertensive patients. Renovascular disease in hypertensive patients is progressive in 20 to 40 per cent. The diagnosis of renovascular hypertension can only be made retrospectively after successful intervention. The accuracy of all tests for the determination of the functional significance of a stenosis before intervention remains limited. It has been demonstrated that medical therapy, reconstructive surgical treatment and PTA each can effectively lower high blood pressure. Although medical therapy has been considerably improved because of the development of new drugs, it should be recognized that medical management does not prevent the natural progression of renovascular disease. Therefore, renovascular hypertension is best treated by correction of the underlying renal arterial stenosis. Improvements in surgical management include improved selection of patients for surgical treatment, increased beneficial blood pressure response rates in 70 to 95 per cent of the patients and decreased surgical mortality rates of less than 5 per cent. The anatomic failure rates have been reduced because of the increase in surgical expertise, the use of autologous materials for bypass, the avoidance of combined procedures in the event of concomitant aortoiliac disease, the use of extra-anatomic reconstructions when appropriate and the introduction of extra-corporeal reconstruction and autotransplantation. PTA has evolved as a relatively safe and effective method in the treatment of renovascular hypertension. However, complications do occur and orificial arteriosclerotic lesions and renal arterial branch lesions should not be considered for angioplasty. At present, the question of whether renovascular surgical treatment or PTA should be the treatment of choice cannot be answered completely. Treatment of renovascular hypertension should be accommodated to each patient.
 ...
PMID:Renovascular hypertension. 268 52

To check the reliability of the captopril test and of quantitative radioisotope techniques for the primary diagnosis of renovascular hypertension the data from 41 patients suspected of this disease were retrospectively analysed. In all cases plasma renin activity (PRA) was assayed in peripheral blood and in renal vein blood before and after 25 mg captopril. Double tracer studies with 131I-hippuran and 99mTc-DTPA were also performed, as was renal arteriography. The postoperative blood pressure plots of 23 patients with unilateral renal artery stenosis (who had subsequently been operated upon) were included in the evaluation. Renovascular hypertension was diagnosed in 21 patients and essential hypertension in 20. Twelve of the 20 patients with essential hypertension had renal artery stenosis, but this had not produced renovascular hypertension. The diagnostic significance of the tests as markers of renovascular hypertension was as follows: captopril test P less than 0.001, glomerular filtration fraction P less than 0.02, hippuran clearance P less than 0.001. The captopril test and the quantitative radioisotope techniques were in agreement in identifying patients with renal artery stenosis and renovascular hypertension. False-positive results due to methodological shortcomings can be avoided by applying both methods in succession.
 ...
PMID:[Endocrine and nuclear medicine diagnosis of renovascular hypertension]. 268 83

Renovascular hypertension is relieved by percutaneous transluminal renal angioplasty. In four patients with renovascular hypertension, platelet-activating factor (PAF) was found to be released into the ipsilateral renal venous blood after percutaneous transluminal renal angioplasty, but was not found in the contralateral renal venous blood following this procedure. Anti-platelet-activating factor with a lipid-like property was also found, and its polarity was slightly lower than that of PAF judging by its behavior on thin layer chromatography. Anti-platelet-activating factor completely blocked the aggregation of rabbit platelets induced by PAF, ADP or arachidonic acid. These results indicate that PAF and anti-platelet-activating factor are released into renal venous blood following percutaneous transluminal renal angioplasty in patients with renovascular hypertension.
 ...
PMID:Endogenous platelet-activating factor and anti-platelet-activating factor in patients with renovascular hypertension. 296 84

Renovascular hypertension is the most prevalent form of curable hypertension. Despite some unanswered questions, there is a growing consensus about the need to identify patients with renovascular hypertension so that a specific therapy can be recommended. The renin-angiotensin system is the chief pathophysiologic mechanism responsible for hypertension in patients with renal ischemia but other, yet poorly defined, mechanisms may be operative. Most patients with renovascular hypertension do not present with typical or discriminative clinical features. Thus, many physicians do not perform work-up to uncover renovascular disease even if diagnosis is dictated by patients' clinical course. It is difficult to make the proper diagnosis unless there is a high index of suspicion and certain procedures are performed. How can we, then, select a few patients for the work-up from the vast sea of people with hypertension? The identification of such patients and the pursuit of a renovascular etiology is a matter of clinical judgment. Delineation of renovascular hypertension should be undertaken only after careful deliberation. When clinical clues suggestive of renovascular hypertension are present, appropriate diagnostic tests should be undertaken in patients who are candidates for PTRA or surgery. Captopril-stimulated PRA test is done first. If the test is positive (and in some clinically relevant circumstances even if it is not done or is negative), DSA should be obtained. IV-DSA is being steadily replaced by the superior IA-DSA. The need for renal vein renin determination varies from center to center, but when carefully performed, it yields meaningful information. Ultimately, a conventional arteriogram is done to define the extent of renal artery stenosis and to assess intrarenal vascular anatomy. For selected patients, the benefit-risk ratio clearly outweighs the cost considerations. The spectrum of renovascular hypertension is variable, further compounding the diagnostic indications and contraindications. At one end of this spectrum are those patients in whom surgical therapy is likely to be beneficial, and at the other end are the patients who have relative contraindications to surgery. In between lies the vast gray zone that constitutes a great judgmental challenge in clinical medicine. What is to be done with the patients who have mild to moderate renovascular hypertension whose BP is controlled on medical therapy? There are some patients who may benefit from renovascular repair despite the nonlateralization of renal vein renins. What is the mechanism underlying their hypertension?(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Renovascular hypertension. 306 42

Cardiovascular manifestations of Fabry's disease were studied clinically in 10 hemizygous males and 13 heterozygous females. Mitral valve prolapse was found in 5 of 9 hemizygotes and in 5 of 13 heterozygotes examined by echocardiography. Ordinary medical examinations revealed cardiomyopathy in some asymptomatic females, and the diagnosis of the Fabry heterozygote was established by demonstration of specific inclusion bodies in the biopsied myocardium and low alpha-galactosidase activity in leukocytes. Renovascular hypertension of juvenile onset and thromboembolism were also found in 7 patients. It was concluded that Fabry's disease should always be considered in cases of mitral valve prolapse, cardiomyopathy, renovascular hypertension and thrombosis of unknown etiology, and that the Fabry patients should be followed carefully for the early detection of cardiovascular involvements in this disease.
 ...
PMID:Cardiovascular manifestations in Fabry's disease. A high incidence of mitral valve prolapse in hemizygotes and heterozygotes. 308 63

This paper describes clinical features of high renin hypertension in the elderly. Peripheral plasma renin activity ranged from 0 to 20.1 ng/ml/hr in 59 hypertensive in-patients aged 70 to 86. The patients were divided into 2 groups: 9 cases with plasma renin activity greater than or equal to 3.0 ng/ml/hr (high renin group) and the remaining 50 with plasma renin activity less than 3.0 ng/ml/hr (control group). The development of hypertension differed between the 2 groups. Six of the high renin group (66.7%) had a history of acceleration of previously mild hypertension, while only 3 of the control group (6.0%) had this history (p less than 0.01). The frequencies of high diastolic blood pressure (greater than or equal to 120 mmHg), massive proteinuria (at least 3.0 g/day), hypokalemia (serum potassium less than or equal to 3.0 mEq/L) and high serum cholesterol (greater than or equal to 250 mg/100 ml) were significantly greater in the high renin group than in the control group (p less than 0.01, respectively). Renovascular hypertension was suspected in 6 patients from the high renin group (66.7%), as compared with 1 of the control group (2.0%) (p less than 0.001). There was massive proteinuria in 3 of 6 patients with renovascular hypertension in the high renin group and 2 showed nephrotic syndrome. Thus, two-thirds of the elderly patients with high renin hypertension had probable renovascular hypertension with a history of rapid progression of hypertension.
 ...
PMID:High renin hypertension in the elderly. 329 10

Renovascular hypertension is an unusual complication of renal trauma, occurring in approximately 5% of cases. It occurs predominantly in young males following road traffic accidents (RTA) or blunt abdominal trauma. The interval between injury and development of hypertension varies from two days to 14 years but presentation may be acute with hypertensive encephalopathy. Hypertension developing within a few months of injury may be treated conservatively. Conservative treatment more than one year after injury is associated with an increased risk of persistent hypertension. All cases of renal trauma should be followed with regular blood pressure (BP) recording for at least the first year after injury.
 ...
PMID:Hypertension following renal trauma. 333 26

Treatment of hypertension is changing rapidly because drugs with greater specificity are being developed and knowledge is evolving concerning factors that determine responses to available drugs. For almost a decade US physicians have relied on national guidelines called Stepped-Care. Step 1 calls for using either a diuretic or a beta blocker; in subsequent steps other drugs are added. Because of the new drugs and the new knowledge it is likely that Step 1 will soon be broadened to include many other drugs. The short-term changes in Step-1 will be based upon those factors now known to influence pressure responsiveness: age--young vs old; race--black vs white; type--renovascular vs essential; and severity--mild-to-moderate vs severe. In young hypertensives, much evidence suggests a dominant neurogenic component of central origin; therefore, a central sympatholytic drug or an alpha-beta receptor blocker seem to be preferable as firstline drugs. Hypertension, primarily systolic, in elderly patients responds well to diuretics or calcium channel blockers. Mild-to-moderate hypertension in blacks is particularly responsive to diuretics, while beta blockers are relatively ineffective. Renovascular hypertension is predominantly caused by increased angiotensin II, so converting enzyme (ACE) inhibition is indicated in unilateral stenosis. The hallmark of severe hypertension is vasoconstriction, so a vasodilator (nifedipine, minoxidil, or an ACE inhibitor) is indicated as first treatment, not a diuretic or a beta blocker alone. Long term changes will depend on development of drugs with specificity for newly, or better defined, pressor mechanisms.
 ...
PMID:Predictions for the future of antihypertensive drug therapy. 344 Mar 40

The criteria for selection of patients who may benefit from reconstruction of totally occluded renal arteries are not well defined. Of those patients who underwent renal artery reconstruction for renal artery occlusive disease at our institution 13% (52/397) had a chronic renal artery occlusion at preoperative arteriography. In 38 cases (73%) the contralateral renal artery had a significant (greater than 70%) stenosis, which was reconstructed simultaneously. Renovascular hypertension alone (n = 27;52%) or in combination with impaired renal function (n = 25;48%) was the indication for surgical treatment and transaortic thromboendarterectomy was the preferred method of reconstruction (n = 38;73%). Operative mortality was 5.7% and during follow-up (38 +/- 31 months) 4 patients died from myocardial infarction (n = 2), aortic dissection (n = 1) or cerebral haemorrhage (n = 1). Postoperatively 20 patients (44.5%) had a normal blood pressure; in a further 20 (44.5%) the hypertension was easier to control and medication could be reduced. Five patients (11%) remained hypertensive. Postoperative arteriography showed a normal patent renal artery in 40 cases (89%). Postoperative plasma creatinine levels ranged from 0.8 to 3.4 mg% (1.32 +/- 0.74) which was a significant reduction from preoperative levels. Two patients with severe uraemia improved to an extent where haemodialysis could be discontinued. Radionuclide scan and the measurements of plasma renin activity before and after administration of a converting enzyme inhibitor (Captopril) were the most reliable diagnostic methods for preoperative patient selection and postoperative follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Ten years experience with reconstruction of the chronic totally occluded renal artery. 350 24

Renovascular hypertension is a curable disease that has recently been recognized with increasing frequency. A renal scan in a 1-month-old hypertensive white male showed diminished function of the right kidney, and his peripheral vein renin was elevated. Multiple antihypertensive medications failed to control his hypertension, and right kidney function deteriorated. An arteriogram showed two stenotic renal arteries supplying the right kidney. The smaller inferior artery supplied 35% of the kidney. Selective vein renin levels were greater than 15,000 ng/dL on the right side. Technical considerations in the repair of this lesion included midline transabdominal incision to expose the abdominal aorta and the inferior vena cava; dissection of inferior vena cava (IVC) with division of selected lumbar veins; full mobilization of right kidney and transsection of both renal arteries and the renal vein; perfusion of kidney via each renal artery with cold Sach's solution after resection of arterial stenoses; end-to-side microvascular anastomosis of the smaller (2 mm) renal artery to the main renal artery at the hilum with 10-0 nylon over in situ perfusion cannula; renal artery passed under the IVC to the aorta; and right kidney autotransplanted to a new site on the abdominal aorta with an end-to-side (5.0 mm) renal artery to the aorta and an end-to-side renal vein to IVC anastomosis. Following revascularization, perfusion was excellent and the blood pressure returned to normal. At 6 months follow-up, selective renal vein renins were normal and an arteriogram showed no stenosis. Meticulous dissection, cold perfusion, microvascular anastomosis, and autotransplantation salvaged this kidney and resolved the hypertension.
 ...
PMID:Technical consideration in management of renovascular hypertension in an infant with double renal arteries. 354 Feb 68


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>